Notable Insider Trading: Tonix Pharmaceuticals Holding Corp. $TNXP

99a890b38f0b56fbb33b06470554e372

Tonix Pharmaceuticals Holding Corp. (TNXP) insider have most recently took part in a trading activity. On Dec 26, 2017 Lederman Seth, CEO bought 5,300 shares having total worth of $19,133 at the price of $3.61 per share, following the transaction a total of 116,307 shares owned by Lederman Seth. Before this latest buy, Lederman Seth purchased TNXP at 4 other times during the past twelve months, for a total investment of $188,050 at an average of $3.99 per share.

The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 sell activities .Furthermore, over the past 12 months , the stock was traded 6 times by insiders. In 2 of these trades, the insider was a seller while an employee of the company was the buyer in 4 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 0 1 11.75%
12 Month 4 2 -82.75%

Tonix Pharmaceuticals Holding Corp. (TNXP) last announced its earnings results on Nov 7, 2017. The company reported -0.77 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.70 by $0.07. During the same quarter in the previous year, the company posted -0.29 earnings per share.

2017-11-07 2017-08-14 2017-05-15 2017-04-17 2016-11-10 2016-08-08 2016-05-09 2016-03-04 2015-11-09 2015-08-11
earnings per share -0.77 -0.65 -1.27 -1.78 -0.29 -0.50 -0.74 -0.71 -0.72 -0.73
Revenue(M) 0 0 0 0 0 0 0 0 0 0

Tonix Pharmaceuticals Holding Corp was incorporated on November 16, 2007 under the laws of the State of Nevada as Tamandare Explorations Inc. From inception through October 2011, the Company was involved in the acquisition, exploration and development of natural resource properties in the State of Nevada. On October 11, 2011, the Company changed the name to Tonix Pharmaceuticals Holding Corp. to reflect their new business. The Company is a specialty pharmaceutical company focused on developing pharmaceutical products for challenging disorders of the CNS. They search for potential therapeutic solutions among known pharmaceutical agents that lack regulatory approval for the indications they seek, but which may be approved for use in other indications.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.